Skip to content 
Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel. more
| Dec '22 | Dec '23 | Dec '24 | ||||
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Cost of Revenue | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Gross Profit | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Gross Margin | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Operating Expenses | 2.04M | 1.15M | 1.08M | [{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":56.17,"profit":true},{"date":"2024-12-31","value":52.79,"profit":true}] | ||
| Operating Income | (2.04M) | (1.15M) | (1.08M) | [{"date":"2022-12-31","value":-204200000,"profit":false},{"date":"2023-12-31","value":-114700000,"profit":false},{"date":"2024-12-31","value":-107800000,"profit":false}] | ||
| Total Non-Operating Income/Expense | (128.00K) | 93.00K | (503.00K) | [{"date":"2022-12-31","value":-137.63,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-540.86,"profit":false}] | ||
| Pre-Tax Income | (2.15M) | (1.00M) | (1.55M) | [{"date":"2022-12-31","value":-215200000,"profit":false},{"date":"2023-12-31","value":-100500000,"profit":false},{"date":"2024-12-31","value":-155200000,"profit":false}] | ||
| Income Taxes | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Income After Taxes | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Income From Continuous Operations | (2.15M) | (1.00M) | (1.55M) | [{"date":"2022-12-31","value":-215200000,"profit":false},{"date":"2023-12-31","value":-100500000,"profit":false},{"date":"2024-12-31","value":-155200000,"profit":false}] | ||
| Income From Discontinued Operations | - | - | - | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | ||
| Net Income | (1.71M) | (1.05M) | (1.53M) | [{"date":"2022-12-31","value":-171100000,"profit":false},{"date":"2023-12-31","value":-105100000,"profit":false},{"date":"2024-12-31","value":-153200000,"profit":false}] | ||
| EPS (Diluted) | - | - | (0.09) | [{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-9,"profit":false}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
| NSRX | |
|---|---|
| Cash Ratio | 0.07 |
| Current Ratio | 0.12 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| NSRX | |
|---|---|
| ROA (LTM) | -106.39% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| NSRX | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 5.48 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -4.48 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| NSRX | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.00 |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Nasus Pharma Ltd. (NSRX) share price today is $5.92
Yes, Indians can buy shares of Nasus Pharma Ltd. (NSRX) on Vested. To buy
Yes, you can purchase fractional shares of Nasus Pharma Ltd. (NSRX) via the Vested app. You can start investing in Nasus Pharma Ltd. (NSRX) with a minimum investment of $1.
You can invest in shares of Nasus Pharma Ltd. (NSRX) via Vested in three simple steps:
The 52-week high price of Nasus Pharma Ltd. (NSRX) is $9.99. The 52-week low price of Nasus Pharma Ltd. (NSRX) is $.
The price-to-earnings (P/E) ratio of Nasus Pharma Ltd. (NSRX) is
The price-to-book (P/B) ratio of Nasus Pharma Ltd. (NSRX) is 0.00
The dividend yield of Nasus Pharma Ltd. (NSRX) is 0.00%
The market capitalization of Nasus Pharma Ltd. (NSRX) is $70.06M
The stock symbol (or ticker) of Nasus Pharma Ltd. is NSRX
Consider the share price of Nasus Pharma Ltd. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Nasus Pharma Ltd. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Nasus Pharma Ltd. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Nasus Pharma Ltd. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Nasus Pharma Ltd. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Nasus Pharma Ltd. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
